Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 500 of 866 entries
View as:

Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy

Phase: N/A Priority: Normal
NCT ID: NCT06150729 Org: User:
Start: 09/08/23 End: 05/31/25 Due: 05/31/26

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT01994837 Org: User:
Start: 11/30/13 End: 12/31/14 Due: 12/31/15

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT06067568 Org: User:
Start: 09/28/23 End: 02/26/24 Due: 02/26/25

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT05570006 Org: User:
Start: 03/16/23 End: 12/23/24 Due: 12/23/25

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

Phase: N/A Priority: Normal
NCT ID: NCT06058728 Org: User:
Start: 12/20/23 End: 08/31/26 Due: 08/31/27

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02391480 Org: User:
Start: 04/14/15 End: 07/05/19 Due: 07/05/20

Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

Phase: N/A Priority: Normal
NCT ID: NCT02738125 Org: User:
Start: 04/29/16 End: 12/15/23 Due: 12/15/24

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06107426 Org: User:
Start: 01/24/24 End: 05/31/29 Due: 05/31/30

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT01577550 Org: User:
Start: 04/30/12 End: 05/31/14 Due: 05/31/15

An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

Phase: N/A Priority: Normal
NCT ID: NCT05494606 Org: User:
Start: 08/15/22 End: 03/31/28 Due: 03/31/29

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

Phase: N/A Priority: Normal
NCT ID: NCT02985879 Org: User:
Start: 12/12/16 End: 11/20/19 Due: 11/20/20

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

Phase: N/A Priority: Normal
NCT ID: NCT02668640 Org: User:
Start: 05/01/16 End: 08/13/18 Due: 08/13/19

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02504099 Org: User:
Start: 07/31/15 End: 12/31/16 Due: 12/31/17

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT04499248 Org: User:
Start: 11/16/20 End: 08/31/28 Due: 08/31/29

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Phase: N/A Priority: Normal
NCT ID: NCT03311464 Org: User:
Start: 10/27/17 End: 04/21/20 Due: 04/21/21

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia

Phase: N/A Priority: Normal
NCT ID: NCT02851069 Org: User:
Start: 02/23/17 End: 08/30/18 Due: 08/30/19

Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients

Phase: N/A Priority: Normal
NCT ID: NCT02333383 Org: User:
Start: 12/31/14 End: 08/08/17 Due: 08/08/18

Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05274087 Org: User:
Start: 09/15/20 End: 04/07/21 Due: 04/07/22

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT02609659 Org: User:
Start: 10/28/15 End: 12/28/16 Due: 12/28/17

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

Phase: N/A Priority: Normal
NCT ID: NCT00850044 Org: User:
Start: 02/28/09 End: - Due: -

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02065570 Org: User:
Start: 05/01/14 End: 01/30/20 Due: 01/30/21

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Phase: N/A Priority: Normal
NCT ID: NCT02814916 Org: User:
Start: 03/30/17 End: 01/01/24 Due: 01/01/25

A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth

Phase: N/A Priority: Normal
NCT ID: NCT05454033 Org: User:
Start: 09/07/22 End: 09/03/24 Due: 09/03/25

Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04433442 Org: User:
Start: 08/04/20 End: 06/30/25 Due: 06/30/26

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Phase: N/A Priority: Normal
NCT ID: NCT04026113 Org: User:
Start: 10/01/19 End: 05/29/24 Due: 05/29/25